Index removals put Novavax in focus for passive and active investors

Novavax (NVAX) was recently dropped from several Russell growth benchmarks, including the Russell 2000, 2500, 3000, and Small Cap Growth indices, a reshuffle that can prompt rebalancing by index linked funds.

For you as an investor, these index changes matter less for what they say about Novavax’s business today and more for how they might affect trading volumes, liquidity, and who holds the stock going forward.

Against this index reshuffle backdrop, Novavax’s share price has been volatile, with a 1 day share price return of 2.96% and a 7 day share price return of 13.79% around a latest share price of $9.74. Its year to date share price return of 36.61% and 1 year total shareholder return of 43.24% sit alongside a much weaker 5 year total shareholder return, which highlights recent momentum in the context of a very challenging longer history.

If this kind of sharp move has your attention, it could be a good moment to broaden your watchlist and check out 40 healthcare AI stocks

With Novavax trading at $9.74, alongside an intrinsic value estimate gap and a discount to the average analyst price target, the key question is whether the stock is still mispriced or if the market already reflects its future potential.

Most Popular Narrative: 29.3% Undervalued

On the latest narrative, Novavax’s fair value of $13.78 sits well above the $9.74 share price, which puts the focus firmly on the assumptions behind that gap.

The license agreement with Pfizer, including a US$30m upfront payment and high mid single digit royalties on products containing Matrix M, adds a defined cash inflow and a potential recurring royalty stream that can support enterprise value beyond the core COVID vaccine business.

Curious what kind of revenue erosion, margin reset, and future earnings multiple still point to upside for Novavax at today’s price? The narrative’s model joins declining top line expectations with improving profitability, a premium earnings multiple, and a specific discount rate to bridge from today’s share price to that higher fair value.

Result: Fair Value of $13.78 (UNDERVALUED)

However, the Novavax story can change quickly if partner-led milestones slip or if COVID vaccine demand and competitive pressures reduce the value of future royalty streams.

Next Steps

With sentiment on Novavax split between concern over risks and optimism about potential rewards, it makes sense to act promptly and review the data yourself, starting with the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Novavax?

If Novavax has sharpened your focus, now is the time to widen the lens and look for other stocks that fit your goals before the next move happens.

• Target long-term compounding potential by scanning for quality companies trading below what their fundamentals suggest using the 43 high quality undervalued stocks.
• Prioritize resilience and aim to sleep better at night by focusing on companies flagged in the 75 resilient stocks with low risk scores that score well on overall risk metrics.
• Look for fresh opportunities early by checking the screener containing 18 high quality undiscovered gems, where smaller, less followed stocks with strong fundamentals may still be under the radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.